Literature DB >> 17979263

New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.

Gaëlle Le Bras1, Christine Radanyi, Jean-François Peyrat, Jean-Daniel Brion, Mouâd Alami, Véronique Marsaud, Barbara Stella, Jack-Michel Renoir.   

Abstract

Selective hsp90 inhibitors simultaneously destabilize and deplete key signaling proteins involved in cell proliferation and survival, angiogenesis, and metastasis. Investigation of novobiocin analogues lacking the noviose moiety as novel inhibitors of hsp90 was carried out. A novel series of 3-aminocoumarin analogues has been produced and screened in cell proliferation, and the molecular signature of hsp90 inhibition was assessed by depletion of estrogen receptor, HER2, Raf-1, and cdk4 in human breast cancer cells. This structure-activity relationship study highlights the crucial role of the C-4 and/or C-7 positions of coumarin which appeared to be essential for degradation of hsp90 client proteins. Removal of the noviose moiety in novobiocin together with introduction of a tosyl substituent at C-4 or C-7 coumarins provides 6e and 6f as lead structures which compared favorably with novobiocin as demonstrated by enhanced rates of cell death. The processing and activation of caspases 7 and 8 and the subsequent cleavage of PARP by 6e suggest stimulation of the extrinsic apoptosis pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17979263     DOI: 10.1021/jm0707774

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

2.  Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.

Authors:  Bhaskar Reddy Kusuma; Adam S Duerfeldt; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2011-10-01       Impact factor: 2.823

3.  Identification of a new scaffold for hsp90 C-terminal inhibition.

Authors:  Huiping Zhao; Elisabetta Moroni; Giorgio Colombo; Brian S J Blagg
Journal:  ACS Med Chem Lett       Date:  2013-11-26       Impact factor: 4.345

4.  Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.

Authors:  Huiping Zhao; Alison C Donnelly; Bhaskar R Kusuma; Gary E L Brandt; Douglas Brown; Roger A Rajewski; George Vielhauer; Jeffrey Holzbeierlein; Mark S Cohen; Brian S J Blagg
Journal:  J Med Chem       Date:  2011-05-09       Impact factor: 7.446

Review 5.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

Review 6.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for the C-terminal Domain of Hsp90.

Authors:  Giulia Morra; Marco A C Neves; Christopher J Plescia; Shinji Tsustsumi; Len Neckers; Gennady Verkhivker; Dario C Altieri; Giorgio Colombo
Journal:  J Chem Theory Comput       Date:  2010-08-30       Impact factor: 6.006

8.  Novobiocin Analogues That Inhibit the MAPK Pathway.

Authors:  Jessica A Hall; Sahithi Seedarala; Huiping Zhao; Gaurav Garg; Suman Ghosh; Brian S J Blagg
Journal:  J Med Chem       Date:  2016-01-27       Impact factor: 7.446

Review 9.  Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.

Authors:  Gary E L Brandt; Brian S J Blagg
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

10.  Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold.

Authors:  M Kyle Hadden; Stephanie A Hill; Jason Davenport; Robert L Matts; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2008-12-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.